175 related articles for article (PubMed ID: 1591921)
21. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
22. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
23. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
Alvarez F; Brache V; Tejada AS; Faúndes A
Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
[TBL] [Abstract][Full Text] [Related]
24. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis.
Ling WY; Wrixon W; Acorn T; Wilson E; Collins J
Fertil Steril; 1983 Nov; 40(5):631-6. PubMed ID: 6628707
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
[TBL] [Abstract][Full Text] [Related]
26. Norethisterone contraceptive microspheres.
Rivera R; Alvarado G; Flores C; Aldaba S; Hernandez A
J Steroid Biochem; 1987; 27(4-6):1003-7. PubMed ID: 3695501
[TBL] [Abstract][Full Text] [Related]
27. Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST-1435.
Lähteenmäki P; Weiner E; Lähteenmäki P; Johansson ED; Luukkainen T
Contraception; 1982 Mar; 25(3):299-306. PubMed ID: 6804165
[TBL] [Abstract][Full Text] [Related]
28. Suppression of ovarian function by Microgynon 30 in day 1 and day 5 "starters".
Taylor DR; Anthony FW; Dennis KJ
Contraception; 1986 May; 33(5):463-71. PubMed ID: 3757512
[TBL] [Abstract][Full Text] [Related]
29. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
30. Intravaginal contraception with the synthetic progestin, R2010.
Toivonen J
Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
[TBL] [Abstract][Full Text] [Related]
31. The use of biodegradable norethisterone implants as a 6-month contraceptive system.
Rivera R; Gaitan JR; Ortega M; Flores C; Hernandez A
Fertil Steril; 1984 Aug; 42(2):228-32. PubMed ID: 6745456
[TBL] [Abstract][Full Text] [Related]
32. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.
Olsson SE; Odlind V
Contraception; 1990 Nov; 42(5):563-72. PubMed ID: 2272184
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
34. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
[TBL] [Abstract][Full Text] [Related]
35. Menstrual regulation by sequential hormone therapy.
Beaton JH
West J Surg Obstet Gynecol; 1964; 72():160-3. PubMed ID: 12332438
[TBL] [Abstract][Full Text] [Related]
36. Dynamic testing of hypothalamic-pituitary function in abnormalities of ovulation.
Jones GE; Wentz AC; Rosenwaks Z; Shoemaker J
Am J Obstet Gynecol; 1977 Dec; 129(7):760-76. PubMed ID: 343592
[TBL] [Abstract][Full Text] [Related]
37. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
38. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
[TBL] [Abstract][Full Text] [Related]
39. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Brenner PF; Shoupe D; Mishell DR
Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
[TBL] [Abstract][Full Text] [Related]
40. Intracervical release of ST-1435 for contraception.
Kurunmäki H; Toivonen J; Lähteenmäki PL; Luukkainen T
Contraception; 1984 May; 29(5):411-21. PubMed ID: 6430641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
